Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids
Three semaglutide medications are currently approved by the FDA: Wegovy is approved for weight loss treatment, and can be prescribed to adults and children 12 and older with obesity, as well as some adults with overweight who also have weight-related health problems, such as high blood pressure
They work closely with your provider to ensure you have what you need
Eating high fiber foods like oats, lentils, and vegetables supports the gut bacteria that produce short-chain fatty acids, a direct trigger for GLP-1 secretion
Protect from light Intended Use: For Laboratory Research Use Only Key Characteristics of Retatrutide (10 mg) Triple-Receptor Research Peptide: Designed for experimental engagement of GLP-1, GIP, and glucagon receptors
The SURMOUNT-4 trial assessed the weight maintenance with tirzepatide and had also two periods: a 36-week open-label lead-in period during which all participants took tirzepatide, followed by a 52-week double-blind treatment period during which participants were randomised to either continue on tirzepatide or switch to placebo
